Home » Stocks » TAK

Takeda Pharmaceutical Company Limited (TAK)

Stock Price: $18.41 USD 0.07 (0.38%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 58.04B
Revenue (ttm) 30.50B
Net Income (ttm) 410.02M
Shares Out 1.68B
EPS (ttm) 0.81
PE Ratio 22.73
Forward PE 15.15
Dividend $0.84
Dividend Yield 4.56%

Stock Quote

Trading Day December 3
Last Price $18.41
Previous Close $18.34
Change ($) 0.07
Change (%) 0.38%
Day's Open 18.34
Day's Range 18.34 - 18.50
Day's Volume 722,212
52-Week Range 12.67 - 19.90

More Stats

Market Cap 58.04B
Enterprise Value 103.78B
Earnings Date (est) n/a
Ex-Dividend Date Sep 29, 2020
Shares Outstanding 1.68B
Float n/a
EPS (basic) n/a
EPS (diluted) 0.81
FCF / Share 2.15
Dividend $0.84
Dividend Yield 4.56%
Earnings Yield 4.40%
FCF Yield 12.49%
Payout Ratio n/a
Shares Short 6.35M
Short Ratio 5.27
Short % of Float n/a
Beta 1.10
PE Ratio 22.73
Forward PE 15.15
P/FCF Ratio 8.01
PS Ratio 1.90
PB Ratio 1.26
Revenue 30.50B
Operating Income 930.57M
Net Income 410.02M
Free Cash Flow 7.25B
Net Cash -45.73B
Net Cash / Share n/a
Gross Margin 66.89%
Operating Margin 3.05%
Profit Margin 1.30%
FCF Margin 23.76%
ROA 1.20%
ROE 1.18%
ROIC 1.40%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (13)

Buy 10
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$25.15*
(36.61% upside)
Low
19.6
Current: $18.41
High
31.1
Target: 25.15
*Average 12-month USD price target from 11 stock analysts.

Financial Performance

Financial numbers in millions JPY.

Financial Overview

Year2019201820172016
Revenue3,291,1882,097,2241,770,5311,732,051
Revenue Growth56.93%18.45%2.22%-
Gross Profit2,201,4241,445,4951,274,6101,173,296
Operating Income100,408237,685241,789155,867
Net Income44,241135,192186,886114,940
Shares Outstanding1,6831,683--
Earnings Per Share14.1369.91118.7873.13
EPS Growth-79.8%-41.14%62.42%-
Dividend Per Share--0.811.19
Dividend Growth---32.27%-
Operating Cash Flow896,520373,388407,737302,114
Capital Expenditures-114,504-26,960-64,040-59,031
Free Cash Flow782,016346,428343,697243,083
Cash & Equivalents653,436725,369375,168-
Total Debt5,588,1396,038,3661,106,498-
Net Cash / Debt-4,934,703-5,312,997-731,330-
Assets12,821,09413,792,7734,106,463-
Liabilities8,093,6088,606,7822,089,054-
Book Value4,723,4835,181,9851,997,424-
Numbers in millions JPY, except per-share numbers.

Company Profile

Company Details

Full Name Takeda Pharmaceutical Company Limited
Employees 47,495
CEO Christophe Weber

Stock Information

Ticker Symbol TAK
Stock Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers-Specialty & Generic
Unique Identifier NYSE: TAK

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.